Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1970 2
1971 1
1972 1
1976 1
1977 2
1978 1
1979 2
1980 2
1981 5
1982 4
1983 2
1984 6
1985 1
1986 2
1987 3
1988 7
1989 3
1990 2
1991 3
1992 10
1993 2
1994 10
1995 4
1996 6
1997 9
1998 7
1999 14
2000 2
2001 9
2002 8
2003 11
2004 17
2005 17
2006 18
2007 10
2008 9
2009 16
2010 23
2011 13
2012 16
2013 10
2014 23
2015 9
2016 14
2017 17
2018 17
2019 14
2020 15
2021 25
2022 13
2023 15
2024 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

449 results

Results by year

Filters applied: . Clear all
Page 1
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Louis E, et al. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414. JAMA. 2024. PMID: 39037800 Clinical Trial.
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
CRASH-2 trial collaborators; Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. CRASH-2 trial collaborators, et al. Lancet. 2010 Jul 3;376(9734):23-32. doi: 10.1016/S0140-6736(10)60835-5. Epub 2010 Jun 14. Lancet. 2010. PMID: 20554319 Clinical Trial.
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
CRASH-2 collaborators; Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T. CRASH-2 collaborators, et al. Lancet. 2011 Mar 26;377(9771):1096-101, 1101.e1-2. doi: 10.1016/S0140-6736(11)60278-X. Lancet. 2011. PMID: 21439633 Clinical Trial.
Mammalian zygotic genome activation.
Svoboda P. Svoboda P. Semin Cell Dev Biol. 2018 Dec;84:118-126. doi: 10.1016/j.semcdb.2017.12.006. Epub 2017 Dec 11. Semin Cell Dev Biol. 2018. PMID: 29233752 Review.
Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months.
Edwards P, Arango M, Balica L, Cottingham R, El-Sayed H, Farrell B, Fernandes J, Gogichaisvili T, Golden N, Hartzenberg B, Husain M, Ulloa MI, Jerbi Z, Khamis H, Komolafe E, Laloë V, Lomas G, Ludwig S, Mazairac G, Muñoz Sanchéz Mde L, Nasi L, Olldashi F, Plunkett P, Roberts I, Sandercock P, Shakur H, Soler C, Stocker R, Svoboda P, Trenkler S, Venkataramana NK, Wasserberg J, Yates D, Yutthakasemsunt S; CRASH trial collaborators. Edwards P, et al. Among authors: svoboda p. Lancet. 2005 Jun 4-10;365(9475):1957-9. doi: 10.1016/S0140-6736(05)66552-X. Lancet. 2005. PMID: 15936423 Clinical Trial.
Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial.
Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, Cottingham R, Svoboda P, Brayley N, Mazairac G, Laloë V, Muñoz-Sánchez A, Arango M, Hartzenberg B, Khamis H, Yutthakasemsunt S, Komolafe E, Olldashi F, Yadav Y, Murillo-Cabezas F, Shakur H, Edwards P; CRASH trial collaborators. Roberts I, et al. Among authors: svoboda p. Lancet. 2004 Oct 9-15;364(9442):1321-8. doi: 10.1016/S0140-6736(04)17188-2. Lancet. 2004. PMID: 15474134 Clinical Trial.
A toolbox for miRNA analysis.
Svoboda P. Svoboda P. FEBS Lett. 2015 Jun 22;589(14):1694-701. doi: 10.1016/j.febslet.2015.04.054. Epub 2015 May 7. FEBS Lett. 2015. PMID: 25957774 Free article. Review.
Human antibodies in Mexico and Brazil neutralizing tick-borne flaviviruses.
Cervantes Rincón T, Kapoor T, Keeffe JR, Simonelli L, Hoffmann HH, Agudelo M, Jurado A, Peace A, Lee YE, Gazumyan A, Guidetti F, Cantergiani J, Cena B, Bianchini F, Tamagnini E, Moro SG, Svoboda P, Costa F, Reis MG, Ko AI, Fallon BA, Avila-Rios S, Reyes-Téran G, Rice CM, Nussenzweig MC, Bjorkman PJ, Ruzek D, Varani L, MacDonald MR, Robbiani DF. Cervantes Rincón T, et al. Among authors: svoboda p. Cell Rep. 2024 Jun 25;43(6):114298. doi: 10.1016/j.celrep.2024.114298. Epub 2024 May 29. Cell Rep. 2024. PMID: 38819991 Free article.
Renaissance of mammalian endogenous RNAi.
Svoboda P. Svoboda P. FEBS Lett. 2014 Aug 1;588(15):2550-6. doi: 10.1016/j.febslet.2014.05.030. Epub 2014 May 27. FEBS Lett. 2014. PMID: 24873877 Free article. Review.
449 results